会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • INVASIVE CARDIAC VALVE
    • 入侵心脏瓣膜
    • US20120316642A1
    • 2012-12-13
    • US13519930
    • 2010-12-30
    • Qifeng YuXiang LiuYunlei WangChengyun YueQiyi Luo
    • Qifeng YuXiang LiuYunlei WangChengyun YueQiyi Luo
    • A61F2/24
    • A61F2/2412A61F2/2415A61F2/2418A61F2002/3021A61F2002/9528A61F2002/9534A61F2220/0075A61F2230/0021A61F2230/0023A61F2230/0054A61F2230/0067A61F2230/008A61F2250/0039
    • An invasive cardiac valve comprises a tubular stent (1) and a valve (2). One end of the tubular stent (1) is of a frusto-conical structure, the other end is wide open, and the diameter of the open end is greater than the diameter of the frusto-conical end. The valve (2) is attached to the frusto-conical end of the tubular stent (1); and a delivery and retrieval hole (4) of the cardiac valve is provided at the top of the open end of the tubular stent (1). Because the diameter of the open end is greater than the diameter of the frusto-conical end, the cardiac valve can be effectively fixed in a position of aortic annulus to prevent the cardiac valve displacement caused by the impact of the blood flow. Because the valve (2) is attached to the frusto-conical end of the tubular stent (1), the valve (2) can totally avoid the left and right coronary ostia and does not affect the haemodynamics of the coronary artery. Because a delivery and retrieval hole (4) of the cardiac valve is provided at the top of the open end of the tubular stent (1), the cardiac valve can be retrieved and reset at any time by handle control if it is found to be placed in an improper position during the release process.
    • 侵入式心脏瓣膜包括管状支架(1)和阀(2)。 管状支架(1)的一端具有截头圆锥形结构,另一端敞开,开口端的直径大于截头圆锥端的直径。 阀(2)连接到管状支架(1)的截头圆锥端; 并且所述心脏瓣膜的输送和取出孔(4)设置在所述管状支架(1)的开口端的顶部。 因为开口端的直径大于截头圆锥端的直径,所以心脏瓣膜可以有效地固定在主动脉瓣环的位置,以防止由血液流动引起的心脏瓣膜位移。 因为阀(2)附接到管状支架(1)的截头圆锥端,所以阀(2)可以完全避免左冠状动脉和右冠状动脉,并且不影响冠状动脉的血流动力学。 因为心脏瓣膜的输送和取出孔(4)设置在管状支架(1)的开口端的顶部,所以如果发现心脏瓣膜被发现是可以通过手柄控制随时取出和重新设置心脏瓣膜 在释放过程中处于不正确的位置。
    • 4. 发明申请
    • INTERVENTION MEDICAL DEVICE AND PREPARATION THEREOF
    • 干预医疗设备及其准备
    • US20130296806A1
    • 2013-11-07
    • US13703855
    • 2011-06-13
    • Junfei LiXi HuChengyun YueDawei WangPeng HuangZhirong TangQiyi LuoZhaohua Chang
    • Junfei LiXi HuChengyun YueDawei WangPeng HuangZhirong TangQiyi LuoZhaohua Chang
    • A61L27/34
    • A61L27/34A61L27/54A61L31/10A61L31/16A61L2300/42
    • The present invention discloses an interventional medical device and methods of making the same. At least one coating layer is disposed on the outer surface of the interventional medical device and the material of the outmost layer of the coating layer is a sulfonate group-containing polymer. In the present invention, the material of the outmost layer of the interventional medical device is a sulfonate group-containing polymer. The polymer is endowed with a same surface property as that of heparin in addition to appropriate hydrophilicity due to the presence of the sulfonate group. After the interventional medical device is implanted into the human body, a hydrophilic surface is formed on the outer surface of the interventional medical device which is also negatively charged in the body fluid. Therefore, cells can easily adhere and grow on the outer surface thereof as a result of the enhanced cell compatibility. Furthermore, due to a surface property that is the same as that of heparin, the material is provided with excellent anticoagulant properties which inhibit the thrombosis and lower down the incidence rate of post-operational complications.
    • 本发明公开了一种介入医疗装置及其制造方法。 至少一个涂层设置在介入医疗装置的外表面上,涂层的最外层的材料是含磺酸基的聚合物。 在本发明中,介入医疗装置的最外层的材料是含磺酸基的聚合物。 由于存在磺酸盐基,除了适当的亲水性之外,聚合物具有与肝素相同的表面性质。 在将介入医疗装置植入人体后,在介入医疗装置的外表面上形成亲水性表面,其也在体液中带负电。 因此,由于细胞相容性的增强,细胞可以容易地附着和生长在其外表面上。 此外,由于与肝素相同的表面特性,具有优异的抗凝血性,能够抑制血栓形成,降低手术后并发症的发生率。
    • 5. 发明授权
    • Implantation of encapsulated biological materials for treating diseases
    • 植入包封的生物材料用于治疗疾病
    • US07427415B2
    • 2008-09-23
    • US10684859
    • 2003-10-14
    • David ScharpPaul LattaChengyun YueXiaojie YuJeffrey Alan Hubbell
    • David ScharpPaul LattaChengyun YueXiaojie YuJeffrey Alan Hubbell
    • A61K9/16
    • C12N11/08A61K9/0024A61K9/5031A61K9/5036A61K2035/126C12N5/0012C12N5/0677C12N11/04C12N2533/30C12N2533/74
    • The present invention relates to compositions and methods of treating a disease, such as diabetes, by implanting encapsulated biological material into a patient in need of treatment. This invention provides for the placement of biocompatible coating materials around biological materials using photopolymerization while maintaining the pre-encapsulation status of the biological materials. Several methods are presented to accomplish coating several different types of biological materials. The coatings can be placed directly onto the surface of the biological materials or onto the surface of other coating materials that hold the biological materials. The components of the polymerization reactions that produce the coatings can include natural and synthetic polymers, macromers, accelerants, cocatalysts, photoinitiators, and radiation. This invention also provides methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site. The coating materials can be manipulated to provide different degrees of biocompatibility, protein diffusivity characteristics, strength, and biodegradability to optimize the delivery of biological materials from the encapsulated implant to the host recipient while protecting the encapsulated biological materials from destruction by the host inflammatory and immune protective mechanisms without requiring long-term anti-inflammatory or anti-immune treatment of the host.
    • 本发明涉及通过将包封的生物材料植入需要治疗的患者中来治疗疾病如糖尿病的组合物和方法。 本发明提供了使用光聚合在生物材料周围放置生物相容性涂层材料,同时保持生物材料的预包封状态。 提出了几种方法来完成涂覆几种不同类型的生物材料。 涂层可以直接放置在生物材料的表面上或其它涂覆材料的表面上。 产生涂层的聚合反应的组分可以包括天然和合成聚合物,大分子单体,促进剂,助催化剂,光引发剂和辐射。 本发明还提供了利用这些封装的生物材料通过将它们植入包括皮下部位在内的身体的若干区域来治疗不同的人和动物疾病或病症的方法。 可以操作涂层材料以提供不同程度的生物相容性,蛋白质扩散性特征,强度和生物降解性,以优化从包封的植入物到宿主受体的生物材料递送,同时保护封装的生物材料免受宿主炎症和免疫的破坏 不需要对宿主进行长期抗炎或抗免疫治疗的保护机制。
    • 7. 发明授权
    • Intervention medical device and preparation thereof
    • 干预医疗器械及其制备
    • US09226994B2
    • 2016-01-05
    • US13703855
    • 2011-06-13
    • Junfei LiXi HuChengyun YueDawei WangPeng HuangZhirong TangQiyi LuoZhaohua Chang
    • Junfei LiXi HuChengyun YueDawei WangPeng HuangZhirong TangQiyi LuoZhaohua Chang
    • A61L27/34A61L27/54A61L31/10A61L31/16
    • A61L27/34A61L27/54A61L31/10A61L31/16A61L2300/42
    • The present invention discloses an interventional medical device and methods of making the same. At least one coating layer is disposed on the outer surface of the interventional medical device and the material of the outmost layer of the coating layer is a sulfonate group-containing polymer. In the present invention, the material of the outmost layer of the interventional medical device is a sulfonate group-containing polymer. The polymer is endowed with a same surface property as that of heparin in addition to appropriate hydrophilicity due to the presence of the sulfonate group. After the interventional medical device is implanted into the human body, a hydrophilic surface is formed on the outer surface of the interventional medical device which is also negatively charged in the body fluid. Therefore, cells can easily adhere and grow on the outer surface thereof as a result of the enhanced cell compatibility. Furthermore, due to a surface property that is the same as that of heparin, the material is provided with excellent anticoagulant properties which inhibit the thrombosis and lower down the incidence rate of post-operational complications.
    • 本发明公开了一种介入医疗装置及其制造方法。 至少一个涂层设置在介入医疗装置的外表面上,涂层的最外层的材料是含磺酸基的聚合物。 在本发明中,介入医疗装置的最外层的材料是含磺酸基的聚合物。 由于存在磺酸盐基,除了适当的亲水性之外,聚合物具有与肝素相同的表面性质。 在将介入医疗装置植入人体后,在介入医疗装置的外表面上形成亲水性表面,其也在体液中带负电。 因此,由于细胞相容性的增强,细胞可以容易地附着和生长在其外表面上。 此外,由于与肝素相同的表面特性,具有优异的抗凝血性,能够抑制血栓形成,降低手术后并发症的发生率。
    • 8. 发明授权
    • Invasive cardiac valve
    • 有创性心脏瓣膜
    • US09095431B2
    • 2015-08-04
    • US13519930
    • 2010-12-30
    • Qifeng YuXiang LiuYunlei WangChengyun YueQiyi Luo
    • Qifeng YuXiang LiuYunlei WangChengyun YueQiyi Luo
    • A61F2/06A61F2/24A61F2/30
    • A61F2/2412A61F2/2415A61F2/2418A61F2002/3021A61F2002/9528A61F2002/9534A61F2220/0075A61F2230/0021A61F2230/0023A61F2230/0054A61F2230/0067A61F2230/008A61F2250/0039
    • An invasive cardiac valve comprises a tubular stent (1) and a valve (2). One end of the tubular stent (1) is of a frusto-conical structure, the other end is wide open, and the diameter of the open end is greater than the diameter of the frusto-conical end. The valve (2) is attached to the frusto-conical end of the tubular stent (1); and a delivery and retrieval hole (4) of the cardiac valve is provided at the top of the open end of the tubular stent (1). Because the diameter of the open end is greater than the diameter of the frusto-conical end, the cardiac valve can be effectively fixed in a position of aortic annulus to prevent the cardiac valve displacement caused by the impact of the blood flow. Because the valve (2) is attached to the frusto-conical end of the tubular stent (1), the valve (2) can totally avoid the left and right coronary ostia and does not affect the haemodynamics of the coronary artery. Because a delivery and retrieval hole (4) of the cardiac valve is provided at the top of the open end of the tubular stent (1), the cardiac valve can be retrieved and reset at any time by handle control if it is found to be placed in an improper position during the release process.
    • 侵入式心脏瓣膜包括管状支架(1)和阀(2)。 管状支架(1)的一端具有截头圆锥形结构,另一端敞开,开口端的直径大于截头圆锥端的直径。 阀(2)连接到管状支架(1)的截头圆锥端; 并且所述心脏瓣膜的输送和取出孔(4)设置在所述管状支架(1)的开口端的顶部。 因为开口端的直径大于截头圆锥端的直径,所以心脏瓣膜可以有效地固定在主动脉瓣环的位置,以防止由血液流动引起的心脏瓣膜位移。 因为阀(2)附接到管状支架(1)的截头圆锥端,所以阀(2)可以完全避免左冠状动脉和右冠状动脉,并且不影响冠状动脉的血流动力学。 因为心脏瓣膜的输送和取出孔(4)设置在管状支架(1)的开口端的顶部,所以如果发现心脏瓣膜被发现是可以通过手柄控制随时取出和重新设置心脏瓣膜 在释放过程中处于不正确的位置。
    • 10. 发明申请
    • IMPLANTATION OF ENCAPSULATED BIOLOGICAL MATERIALS FOR TREATING DISEASES
    • 用于治疗疾病的包埋生物材料的植入
    • US20090004238A1
    • 2009-01-01
    • US12197040
    • 2008-08-22
    • David ScharpPaul LattaChengyun YueXiaojie YuJeffrey Alan Hubbell
    • David ScharpPaul LattaChengyun YueXiaojie YuJeffrey Alan Hubbell
    • A61K45/00A61P25/00A61P9/00A61P17/00A61P3/00A61P37/00A61K9/48
    • C12N11/08A61K9/0024A61K9/5031A61K9/5036A61K2035/126C12N5/0012C12N5/0677C12N11/04C12N2533/30C12N2533/74
    • Methods of applying biocompatible coating materials around biological materials using photopolymerization while maintaining the pre-encapsulation status of the biological materials are disclosed. The coatings can be placed directly onto the surface of the biological materials or onto the surface of other coating materials that hold the biological materials. The components of the polymerization reactions that produce the coatings can include natural and synthetic polymers, macromers, accelerants, cocatalysts, photoinitiators, and radiation. Methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site are also disclosed. The coating materials can be manipulated to provide different degrees of biocompatibility, protein diffusivity characteristics, strength, and biodegradability to optimize the delivery of biological materials from the encapsulated implant to the host recipient while protecting the encapsulated biological materials from destruction by the host inflammatory and immune protective mechanisms without requiring long-term anti-inflammatory or anti-immune treatment of the host.
    • 公开了在保持生物材料的预包封状态的同时使用光聚合在生物材料周围应用生物相容性涂层材料的方法。 涂层可以直接放置在生物材料的表面上或其它涂覆材料的表面上。 产生涂层的聚合反应的组分可以包括天然和合成聚合物,大分子单体,促进剂,助催化剂,光引发剂和辐射。 还公开了利用这些包封的生物材料通过将它们植入体内包括皮下部位的几个区域来治疗不同的人和动物疾病或病症的方法。 可以操作涂层材料以提供不同程度的生物相容性,蛋白质扩散性特征,强度和生物降解性,以优化从包封的植入物到宿主受体的生物材料递送,同时保护封装的生物材料免受宿主炎症和免疫的破坏 不需要对宿主进行长期抗炎或抗免疫治疗的保护机制。